RxDoctor Payments Data

Brian Taber, MD

Family Medicine · Lompoc, CANPI 1811903131

Payments from drug & device makers

$859in general payments, 2019–2025

Across 37 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$234
  • Welch Allyn$136
  • GSK$119
  • Lilly USA, LLC$99
  • Novo Nordisk$59
  • Exact Sciences$58
  • plus $154 from 6 others

What the payments were for

  • Food & beverage$72384%
  • Other$13616%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$859 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$254,985
Medicare patients
356
Services billed
6,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$66,266
JardianceEmpagliflozin35$42,673
JanuviaSitagliptin Phosphate36$39,003
XareltoRivaroxaban20$29,442
EliquisApixaban23$26,301
TrulicityDulaglutide15$22,322
FarxigaDapagliflozin Propanediol15$9,448
Wixela InhubFluticasone Propion/Salmeterol12$2,348
Atorvastatin Calcium248$2,295
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,172
Omeprazole151$2,045
Gabapentin63$1,625
Ezetimibe43$1,521
Estradiol36$1,332
Metoprolol Succinate67$1,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$59$66,26656 claims
MerckJanuvia$22$39,00336 claims
Johnson & JohnsonXarelto$18$29,44220 claims
PfizerEliquis$234$26,30123 claims
Lilly USA, LLCTrulicity$99$22,32215 claims
AstraZenecaFarxiga$36$9,44815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Lompoc

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →